Transcript

GLP-1 weight regain and doctors forced out of Gaza

From The BMJ · Episode page · Watch on YouTube

· 32 min · 4,765 words · 42 timestamped sections

This is the full, timestamped transcript of "GLP-1 weight regain and doctors forced out of Gaza", an episode of The BMJ published January 12, 2026 (32 min, about 4,765 words). It mentions 10 people, works and ideas, including Sam West, GLP-1 drugs, Muhammad Abu Mugab, MSF, Cameron Abassi.

What this episode is about

The discussion focuses on recent findings regarding weight regain after the cessation of GLP-1 receptor agonists, highlighting that patients experience a more rapid return to previous weight compared to those who participated in behavioral programs. Additionally, it addresses the challenges faced by medical charities in Gaza due to new Israeli regulations, emphasizing the ethical dilemma of leaving patients behind during evacuations.

Key takeaways

  • GLP-1 drugs are great for weight loss, but stopping them is like pulling the rug out from under your diet.
  • Patients regain weight quickly after stopping GLP-1s; they could be back to square one in just 1.7 years.
  • Obesity medications cut weight effectively, yet half of users quit within a year—talk about a disappearing act!
  • Surprisingly, improved metabolic metrics vanish along with the weight, leaving health risks lurking beneath the surface.
  • Patients need transparency: fantastic for weight loss, but understand the swift rebound—weight management isn’t a set-it-and-forget-it affair.

Who speaks in this episode?

What is discussed, and when

  1. – 5:00: simaglletide, tepatide, Sam West, GLP-1 drugs
  2. – 10:00: simaglletide
  3. – 15:00: tepatide
  4. – 20:00: Muhammad Abu Mugab, Doctors Without Borders
  5. – 25:00: Doctors Without Borders
  6. – 30:00: MSF
  7. – 31:43: Cameron Abassi

Notable quotes from "GLP-1 weight regain and doctors forced out of Gaza"

  • Welcome to the Medicine Science podcast from the BMJ. I'm Cameron Abassi, editorinchief. This week, research on weight regain after GLP1 receptor agonists. What happens when you stop.
    about Cameron Abassi · at
  • My name is Sam West. I'm a post-doal researcher at the University of Oxford.
    about Sam West · at
  • When we focus on simaglletide and seepide only, people lose more weight.
    about simaglletide · at
  • Skills that they've learned during the diet. M let's look at this now from a kind of health policy perspective because we talked about you know health systems around the world not just in the UK but in the UK also are funding these.
    about Nav Lauder · at
  • Lastly, we turn to the ongoing health catastrophe in Gaza. The international charity Metans Frontier or Doctors Without Borders is the BMJ's choice for our charity appeal this…
    about Doctors Without Borders · at
  • Then in 2007, I became the medical reference for the MSF programs, medical programs in Gaza.
    about Muhammad Abu Mugab · at
  • MSF currently supports one in five hospital beds and one in three births in Gaza. In 2025 alone, we provided nearly 800,000 outpatient consultations, treated over a 100,000 trauma cases,.
    about MSF · at

Who and what is mentioned in this episode?

People

  • Sam West — Person · Main guest (research interviewee) · 2 mentions · first at
    Explains the BMJ-published systematic review/meta-analysis quantifying weight regain after stopping weight-loss medications (including semaglutide/tirzepatide) and discusses clinical and policy implications.
  • Muhammad Abu Mugab — Person · Main speaker (field interviewee) · 1 mention · first at
    Palestinian MSF doctor interviewed about conditions in Gaza, risks to health workers, and the impact of Israeli regulations on humanitarian medical operations.
  • Cameron Abassi — Person · Host · 2 mentions · first at
    Introduces the episode, frames the two main segments (GLP-1 weight regain research and Gaza/MSF access issues), and closes the show.
  • Nav Lauder — Person · Interviewer / segment lead · 1 mention · first at
    BMJ UK research editor who leads the interview with Sam West, guiding discussion on methods, findings, and implications for clinicians and health systems.

Companies & orgs

  • MSF — Company · Case study · 1 mention · first at
    MSF is a key medical charity providing life-saving care in Gaza, facing operational challenges due to new Israeli regulations.
  • Doctors Without Borders — Company · Case study · 2 mentions · first at
    Doctors Without Borders is another name for MSF, highlighting its international presence and mission.
  • BMJ — Company · Business focus · 1 mention · first at
    BMJ is the publisher of the podcast and the platform where the discussed research is published.
    Common result after stopping GLP-1 drugs, even in trials and under experimental conditions. But new research just published on bmj.com aims to quantify what is happening in the…

Products & tech

  • simaglletide — Product · Case study · 4 mentions · first at
    Simaglletide is a weight loss medication discussed in the podcast, with research highlighting rapid weight regain after cessation.
  • tepatide — Product · Case study · 4 mentions · first at
    Tepatide is another weight loss medication discussed alongside simaglletide, with similar findings on weight regain.
    When we focus on simaglletide and seepide only, people lose more weight.

Concepts & topics

  • GLP-1 drugs — Concept · Core topic · 1 mention · first at
    GLP-1 drugs are the main focus of the podcast, discussing their effectiveness and the implications of stopping their use.
    First this week, GLP-1 drugs. It's well established that weight regain is a common result after stopping GLP-1 drugs, even in trials and under experimental conditions. But new.

Full transcript with timestamps

Welcome to the Medicine Science podcast from the BMJ. I'm Cameron Abassi, editorinchief. This week, research on weight regain after GLP1 receptor agonists. What happens when you stop taking weight loss drugs? We found that people who took medication lost more weight compared with those who took part in a behavioral program. But the weight regain was much more rapid after medication compared with people who had taken part in behavioral programs. We also look to Gaza where new Israeli regulations on aid workers are making the work of medical charities like Medsan Son Frontier much more difficult. Even with the warnings from the Israeli army to evacuate the hospital, they were refusing. And I think that's ethically right. They cannot leave patients behind. I mean, you have not all the patients can leave and walk.

First this week, GLP-1 drugs. It's well established that weight regain is a common result after stopping GLP-1 drugs, even in trials and under experimental conditions. But new research just published on bmj.com aims to quantify what is happening in the here and now for patients who stop using these weight loss drugs. Nav lauder, our UK research editor, finds out more.

My name is Sam West. I'm a post-doal researcher at the University of Oxford. Thanks so much for joining us uh on this podcast today to talk about um your recently published research paper which has been getting a lot of attention because you're looking at weight regain after um using weight loss medications which is uh you know one of the the hot topics of our time really. Um, you know, for those of us working in clinical medicine, we've obviously spent the last few years marveling at how effective these medications are at helping um, patients lose weight and of course manage diabetes, which is, you know, what they were originally intended for, but you have been doing some research that's looking at the other side of the curve and what happens when people stop taking these medications. So, why don't you tell us a little bit more about um, what you did? So the new obesity medications simaglletide and tepatide

are transforming the treatment of obesity um with people in clinical trials losing around 15 to 20% of their body weight. But what we also see is that around half of people discontinue taking the medication within 12 months of starting. [sighs] So we were interested to see what happens to people's body weight after the medication stops. To look at this, we identified studies that had given people medication for weight loss and importantly followed them up afterwards after the treatment had stopped. We focused on any medication, those that had been licensed previously and since discontinued right to those that are being prescribed now.

In total, we identified 37 studies that had given people weight management medication. And also given the focus on simaglletide and tepatide, we also did a subgroup analysis of studies that had just focused on these and there were six studies in total that had used simaglletide oride.

And um what did you find? So when we look at people taking any medication, we find that they lose 8.3 kg during treatment, but then within the first year after stopping, they regain 4.8 kg and they're estimated to return to their baseline body weight within 1.7 years after stopping taking the medication. When we focus on simaglletide and seepide only, people lose more weight. they lose around 14.7 kg but then they regain 9.9 kg then within the first year of stopping. Um it's important to note here that we only have 12 months of followup for people who were given saragllet to zepatide but we were able to produce a projected estimate that people will return to baseline weight within 1 and 1/2 years after stopping medication. We also looked at different cardium metatabolic risk factors with that. So things like um HBA1C, fasting glucose, blood lipids and blood pressure. And we found that they also

decreased with treatment but returned to baseline virtually in parallel with weight regain such that they were back at baseline within 1.4 years. So that's really interesting because I think that's been one of one of the concerns when you know as a GP I sometimes talk to people who are interested in starting these medications and we all there's this kind of sense that the the weight comes back once you stop taking them. Um but it's very helpful to see this kind of quantified. I don't think I've seen um this kind of quantification before.

And I think this has implications for you know the way we council people about taking these medications um and also the way you know there's a big plan within the NHS where that this is they're being rolled out and launched and I guess this influences how we might think about the kind of cost effectiveness of these medications as well. So can you just talk to us a little bit about the what do you think are the kind of clinical implications for an individual patient?

Yeah, I think you touched on the key implications there. It's important that people going into treatment are aware of the risks at the minute. 90% of the people in the UK who are taking this medication are accessing it privately and paying for it for themselves. So they now have this information of the rapid weight regain after treatment stops to make their own informed decisions about this. And also for clinicians who are counseling patients about the best approaches to manage their weight. Clinicians can now have fully informed conversations with patients about the benefits of these medications. They're clearly very effective for weight loss, but also the very real possibility that people re will regain much of the weight after the treatment has stopped. And do we know if um because you mentioned the weight we gain and also then that the improvements that have been shown in studies in things

like blood pressure and lipids and glucose that you you found that those also um are reversed to an extent when this medication is stopped. Do we know much about whether are these medications just useful for then for that window that people are taking them? Do those effects last? Is that something that needs to be studied further? Yeah, that's one of the key limitations I think to the study. So we do find that those cardometabolic risk factors return to baseline within 1.4 years of stopping any medication for weight loss. It's important to caveat that is not just for simaglletide to zepatide. But what we don't have is data beyond that to know whether this has any um changes for hard outcomes. Um, so those long-term real world data are going to be really helpful

and that I guess is just a limitation of the follow-up of the trials that are included in your review that the follow these new medications that followup I guess is happening now and isn't there at the moment.

Precisely. Yeah. They just haven't been around for long enough for us to have this long-term data. Of course, they've been used for diabetes for many years, but at these doses where they're inducing such weight loss, we don't have the long-term follow-up yet, which I think is also important in the counseling of patients as well is that, you know, this is these are still live questions because I I imagine lots of people will have, you know, these kinds of questions. Um, another thing that I thought was really interesting is what did you find about the the rate of weight regain the amount of weight lost? Did that have any bearing on how quickly or not weight was regained?

Yeah. So one of the we had previously conducted a similar systematic review where we looked at the rate of weight regain after behavioral interventions and we found that the rate the amount the rate of weight regain was dependent on the amount of weight lost during treatment such that more weight lost equals faster weight regain. And that was also consistent across our review where we found that the more weight that was lost with medication also resulted in faster weight regain. interesting. And um it's interesting that you be you bring in um the sort of behavioral interventions because I think one of the other notable findings was that the weight regain um after stopping medication seems to be faster than after you stop behavioral programs. Is that right?

Yeah. So because we had this data from the previous systematic review, we took the opportunity to do an indirect comparison of the two. Um so we found that people who took medication lost more weight compared with those who took part in a behavioral program. But the weight regain was much more rapid after medication compared with people who had taken part in behavioral programs. So after medication, people were estimated return to return to their baseline weight after 1.7 years, whereas people who had finished a behavioral program weren't estimated to return to baseline until um just under four years. And as I said, the amount of weight lost is predictive as of how fast people regain the weight. So we thought that perhaps this difference in weight regain could be explained by the fact that people just lost more weight by taking medication. So we did a further analysis where we broke down the amount of weight

lost into averages of 5 10 and 15 kg. And we found that, as I said before, more weight loss equals faster weight regain. But we saw consistently faster weight regain with medication regardless of how much weight was lost. That's really fascinating because I think um you know just in thinking about how these medication works I guess you could sort of say well these behavioral programs might be teaching or you know involving skills about uh your dietary intake u movement and exercise as well as kind of I don't know other techniques that might help manage the way you eat and how you eat but the these medications as well I think there's also some uncert certainty about whether they affect the they they might have some long-term effect as well, but I guess that that's not borne out by the the evidence.

Yeah, I think you've touched on it there. When you're part of a a a behavioral program, you're often taught ways of managing to taught ways to manage your hunger while you're losing weight. Whereas the medications work to remove or dampen those feelings of hunger. But when the medication stops, if you haven't been given coping skills to manage the feelings of hunger when they come back, then there's no recourse to help manage the weight after

treatment. Whereas those who might have finished a behavioral program can continue to implement the different skills that they've learned during the diet. M

let's look at this now from a kind of health policy perspective because we talked about um you know health systems around the world not just um in the UK but in the UK also um are funding these medications and and probably in a lot of places trying to expand the funding of these um medications but these drugs are expensive you know if we're thinking about semiglutide and um tepatide and if the benefits you know can be reversed So quickly upon stopping, how do you think health systems should consider the value of these medications? Are we, you know, should do they need to be prescribed lifelong? How do we kind of grapple with that?

I think one of the implications of this research is that we can at least reopen the discussion around the cost effectiveness of these medications. Speaking specifically about the UK, when licensing these medications, NICE perform cost effective analysis before they can be licensed within the NHS. Um, they did that using their standard process with the data that was available. and they assumed that people would regain their body weight over 3 years and found that these came in at a cost of £16,000 per qual. Um, just to note the nice willingness to pay threshold is £20,000.

So, as long as it comes below that, they're considered cost effective. Um, but when they performed a scenario analysis and assumed people would regain weight over two years, they came in at £21,000. So just exceeding that threshold. So I think it would be interesting at least to revise this model with the new weight regain data that we have. previously mice have done all this work with assumed weight regain. We now have the hard data to show that it's faster than those assumptions. So it I think at least it reopens the conversation for us to revisit those models.

It's yeah it's something that um could and perhaps should be looked at again. Um actually I've just thought of one other thing that I want to ask you which is for people who are already taking these medications I guess there might be some concern now about well when I stop you know what what's going to happen how are there is there anything available for people to help I guess soften the landing or provide support what what or what resources might you suggest or um strategies might you suggest for people who want to come off but are now worried about weight regain So, one of the other things that we looked at in our review was the relationship that behavioral support during treatment would have. Um, and we found that intensive behavioral support during treatment with the medication helped people lose more weight. So, people provided with intensive support lost 4 and a half kilos more than those

provided with very little or no support at all. But unfortunately, we found that behavioral support during treatment or after treatment didn't affect how fast people regain the weight afterwards. So, we don't really have a clear picture of what needs to happen at the end of medication or even during treatment with medication to prevent the weight regain. Clearly, some people will effectively keep the weight off. Some people will regain it faster than what we found. That's the nature of averages. What we need to do is find out what's working after medication. One caveat to the work that we've done here is that we have synthesized data from clinical trials. And the type of person that takes part in a clinical trial and the environment of a clinical trial is very different to that of the real world.

people are often more motivated to lose weight and there's a lot more support. You're being monitored the whole time that you're on the study. Um, in some studies, people were given monthly meetings with dieticians or physicians. Um, and that is very likely different to what's happening in real world settings both in the NHS and for people who are accessing the medication privately. So what we need next are real world assessments of how these medications are being used in the real world. That goes for the clinical characteristics of the people who are using them in the NHS and privately. the scale of weight loss that happens in these settings, what type of behavioral support is being provided to people who are being given the medication, and we can continue to monitor discontinuation rates and also weight regain for those that stop taking it.

And that article, weight regain following the secession of medication for weight management is available via open access on bmj.com. Lastly, we turn to the ongoing health catastrophe in Gaza. The international charity Metans Frontier or Doctors Without Borders is the BMJ's choice for our charity appeal this Christmas season. They've been providing life-saving care for Garzans whilst acting on their principle of tmoage or bearing witness to the suffering that they are seeing. On the 30th of December, 37 NOS's including MSF and Oxfam were told by Israel that the registrations necessary for their aid workers to operate in Gazen clinics and hospitals would expire the next day. They now have a 60-day window to end all operations in the Gaza Strip and the West Bank, including East Jerusalem. Overall, around 60% of Gaza's field hospitals are run or supported by such international non-governmental

organizations. As of the time of recording for this podcast, Wednesday, January the 7th, this order has not been rescinded. Our reporter, Elizabeth Mahes, is covering the story and tells us more. My name is Muhammad Abu Mugab. I joined MSF 22 years ago uh as a general practitioner supporting uh the mobile clinic activities and mental health activities. Then in 2007, I became the medical reference for the MSF programs, medical programs in in Gaza.

That's Muhammad, a Palestinian doctor who serves as MSF's deputy medical coordinator in Palestine. I spoke to him in late November about the devastating conditions Gazans are suffering through this winter. Widespread heavy rain, flooding, and frigid temperatures alongside continued restrictions on vital aid entering Gaza have left the territory in a desperate situation. Gazans, their homes leveled after years of Israeli bombing, have few options except to attempt to survive the freezing conditions in inadequate tents and makeshift shelters.

Respiratory infections are widespread and the rains have caused sewage to overflow. It has been reported that at least 25 people have died in recent weeks as a result of the extreme weather conditions, including a 29-day old baby who died from hypothermia. This is the state of healthcare in Gaza, and it's only set to get worse. Israel has now reportedly banned dozens of international aid organizations, including MSF, from continuing their work. The NOS's have been given just 60 days or until the 1st of March to leave Gaza. I asked Muhammad about the sense of duty doctors in Gaza feel, especially in the face of threats to their lives and the horrendous conditions that they're living and working in.

I mean the the doctors and paramedics who are working in Gaza and they are really heroes in in terms of heroes because first of all they are part of the population. So they are they are suffering the same as other other you know population is suffering. So they have families who are displaced in in in shelters. Uh they are under risk going and leaving the hospital and leaving their family behind. Uh they are think I mean on on time they are stressed because they know that at any moment they could have in the ER members of their family. And it happened that our colleagues they were working in in in the operating room and they received their children dead and their their family are being critically injured.

And in addition I mean uh with limited of course [snorts] means to to to work. I mean you don't have everything. You don't have the proper enough painkillers and anesthesia drugs. You don't have the enough enough surgical tools. Uh the capacity and the overload of work. I mean they could they could [clears throat] operate two to three patients in the operating room or operate patients on the floor. So patients in in Gaza during the war they were I never see saw this in my life that patients who need surgery were waiting in cues to have their surgery and patient even who need intensive care unit were waiting in cues to be admitted in the intensive care unit.

Uh and finally of course I mean the starvation I mean uh uh what has been uh the population suffer it was the as well the medical stuff the medical stuff were [snorts] starved they were having an acute hunger I mean they were completely exhausted tired there was no food to buy I mean in the market I mean so they were with really no energy to you know but still they were coming as you said and even with the warnings from the Israeli army to evacuate the hospital they were refusing and I think that's ethically right they cannot leave patients behind I mean you have not all the patients can leave and walk you have patients in the operating room you have patients in the intensive care unit you have babies in the incubators you have patients and even in the ward that cannot move so you cannot leave the patient patients and who are in the hospital and just obey the orders and leave so they had the

ethics to stay and they The consequence is that they were arrested and they were tortured and they were some of them have been killed because of this.

On New Year's Eve, December 31st, Israel revoked the operating licenses of 37 aid groups, including MSF and Oxfam, for failing to comply with new registration requirements. The new rules mean that international NOS's operating in Gaza and the West Bank must provide Israeli officials with detailed information on their Palestinian staff members. Fearful for the safety of their staff, aid groups are reluctant to comply. Israeli officials have alleged that some NOS's, including MSF, have employed staff with links to armed militants, something the MSF has strongly denied. Here's Claire Sanfalippo, MSF's emergency coordinator for Palestine, speaking about the situation. As of December 31st, MSF is still awaiting renewal of its registration to operate in Gaza and the West Bank under new Israeli requirements, including staff lists.

Despite months of engagement, no clear criteria or safeguards have been provided. On December 30th, Israeli authorities publicly accused MSF staff of links to armed groups. MSF takes such accusations extremely seriously and would never knowingly employ anyone engaged in military activity. Such unsubstantiated public claims put humanitarian staff at risk and undermine life-saving medical work. The Palestinian health system is decimated. essential infrastructure destroyed and people struggle to meet basic needs. People need more humanitarian aid, not less. If MSF and other international non-governmental organizations lose access, hundreds of thousands of Palestinians will be cut off from essential healthcare.

MSF currently supports one in five hospital beds and one in three births in Gaza. In 2025 alone, we provided nearly 800,000 outpatient consultations, treated over a 100,000 trauma cases, performed 22,700 surgeries, assisted more than 10,000 births, and distributed nearly 700 million litters of water. Reports suggesting that MSF has failed to comply with registration rules are inaccurate. We have been fully engaged since July 2025 and submitted most of the required information. MSF continues to seek dialogue with Israeli authorities so that we can deliver vital and critical health services and support Gaza's decimated health system.

More than 500 humanitarian workers have been killed in Gaza since the 7th of October 2023, while at least 1,700 health workers have been killed as of the 6th of October 2025. That's around two a day and healthcare facilities have also continually come under attack by Israel. Many Palestinian doctors have also been arrested and taken away by Israeli forces. I asked Muhammad about the doctors who have been detained by Israel and the horrifying reports of torture and in some cases death that have come to light. I also spoke to him about MSF doctor Muhammad Obed who is still being held by Israel and whether there have been any updates on his situation.

Uh uh until now we don't know nothing. I mean now it's it's followed by the I mean lawyers that MSF is as well following with. [snorts] But I mean Dr. Dr. Mohammed Abid is an orthopedic surgeon that has been working with MSF in the reconstructive unit. He's he's a very experienced orthopedic surgeon and he didn't want to leave the hospitals because I mean you cannot ask a doctor an orthopedic in a trauma surgery in a in a war zone to leave his patients and and leave the hospital. That's that's that's that's the only crime that doctors and like Dr.

Muhammad Abid has been charged of not leaving the hospitals after the order by the to leave the hospitals and I and I think that that's that has to be of course I mean [snorts] this I mean investigated later and you know the doctors that has been luckily uh released I mean they have a horrible stories about about uh uh the treatment inside the the prison and the fortunately I mean physical has been physical uh abuse and all of this kind of things.

Look before leaving actually uh uh uh Gaza one a few days two days before leaving Gaza I will describe to you the hospital that NASA hospital is one of the biggest hospitals in the in the south in Kunes. So in in the uh two days before I left I went to say goodbye to the to the team. I mean that I'm I'm leaving and and when I entered NASA hospital the MSF unit patients were on the floor. There was no space. Patients were on their mattresses you know just uh on on both side of the corridors. It was more than 200% of the pupy rate it it reached in in in NASA hospital.

patients were shouting, crying from pain. Uh the smell of of you know the infected uh wounds and blood obviously I couldn't really stand for more than 5 minutes in in in the uh wards of MSF even with all our capacity with all our means but the the the number of patients were injured were high. I mean uh since since the declaration of ceasefire uh there was always been air strikes and bombing that didn't stop uh a lot of people have been killed and injured a majority of them 60% children and women so I mean there is no excuse about targeting any kind of military Palestinian fighters [snorts] or whatever Hamas no it's it's mainly obviously children where the main target and which we reach now more than nearly 20,000 children killed and 10,000 of the of women have been as well killed. So I mean it's it's and the aid is I mean it's still under restriction. I mean yes aids and entering but there is always

restrictions. There is what is called dual use. I mean you cannot bring all medical items because they say okay this item is a dual use so you cannot prevent it. So, so I mean it's it's really uh uh the the ceasefire didn't improve the the the situation. The people the people still are actually in the tents and their shelter. So, they didn't go actually back to their homes because there is no homes anymore. The Gaza has been destroyed. Plus, now they are they they are all living in in a very tiny region. I mean uh when you see the map, there is the yellow line that takes all east of Gaza strip. So the people are squeezed only on the west side of Gaza which Gaza before 7th October was one of the dense [clears throat] areas in the world. I mean with with 2 million point two people uh living there.

As of the time we're recording this the 7th of January MSF has said it's exploring all options when it comes to continuing its work in Palestine. The charity has applied for re-registration and is actively engaging with Israeli authorities with the hope of making this happen. Their application is still pending. Palestine is just one of the countries where MSF is currently working to provide vital and life-saving healthcare. You can read more about their work in places like Sudan and Nigeria on the BMJ's website. That's bmj.com.

A reminder that MSF is our charity of choice for the BMJ Christmas appeal. And you've heard how important their work is. There is still time to donate to support them and we've added links to the podcast notes to do so. Please give if you can. That's it for this week. We'll be back soon with more medicine and science from the BMJ. Until then, I'm Cameron Abassi. Thanks for listening.

Questions about this episode

Who speaks in "GLP-1 weight regain and doctors forced out of Gaza"?

Cameron Abassi (Host), Sam West (Guest), Muhammad Abu Mugab (Guest), Claire Sanfalippo (Guest).

What is "GLP-1 weight regain and doctors forced out of Gaza" about?

The discussion focuses on recent findings regarding weight regain after the cessation of GLP-1 receptor agonists, highlighting that patients experience a more rapid return to previous weight compared to those who participated in behavioral programs. Additionally, it addresses the challenges faced by medical charities in Gaza due to new Israeli regulations, emphasizing the ethical dilemma of…

What is mentioned in this The BMJ episode?

10 people, works and ideas are mentioned, including Sam West, GLP-1 drugs, Muhammad Abu Mugab, MSF, Cameron Abassi, simaglletide. Each one on this page links to its own page with every episode that mentions it.

How long is "GLP-1 weight regain and doctors forced out of Gaza"?

The episode runs 32 min; the transcript is about 4,765 words in 42 timestamped sections.

More from The BMJ

About this transcript: the episode's spoken words as captioned on YouTube, split into timestamped sections. Reclip.Me locates every person, work and idea in the text, keeps the time it is first named, and quotes the words around it verbatim. Last updated January 24, 2026.